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Background: Tumor invasion and metastasis represent a major unsolved problem in cancer pathogenesis. Recent
studies have indicated the involvement of Src-homology 2 domain-containing tyrosine phosphatase 2 (SHP2) in
multiple malignancies; however, the role of SHP2 in oral cancer progression has yet to be elucidated. We propose
that SHP2 is involved in the progression of oral cancer toward metastasis.
Methods: SHP2 expression was evaluated in paired oral cancer tissues by using immunohistochemical staining and
real-time reverse transcription polymerase chain reaction. Isogenic highly invasive oral cancer cell lines from their
respective low invasive parental lines were established using a Boyden chamber assay, and changes in the hallmarks
of the epithelial-mesenchymal transition (EMT) were assessed to evaluate SHP2 function. SHP2 activity in oral cancer
cells was reduced using si-RNA knockdown or enforced expression of a catalytically deficient mutant to analyze
migratory and invasive ability in vitro and metastasis toward the lung in mice in vivo.
Results: We observed the significant upregulation of SHP2 in oral cancer tissues and cell lines. Following SHP2
knockdown, the oral cancer cells markedly attenuated migratory and invasion ability. We observed similar results in
phosphatase-dead SHP2 C459S mutant expressing cells. Enhanced invasiveness was associated with significant
upregulation of E-cadherin, vimentin, Snail/Twist1, and matrix metalloproteinase-2 in the highly invasive clones. In
addition, we determined that SHP2 activity is required for the downregulation of phosphorylated ERK1/2, which
modulates the downstream effectors, Snail and Twist1 at a transcript level. In lung tissue sections of mice, we
observed that HSC3 tumors with SHP2 deletion exhibited significantly reduced metastatic capacity, compared with
tumors administered control si-RNA.
Conclusions: Our data suggest that SHP2 promotes the invasion and metastasis of oral cancer cells. These results
provide a rationale for further investigating the effects of small-molecule SHP2 inhibitors on the progression of oral
cancer, and indicate a previously unrecognized SHP2-ERK1/2-Snail/Twist1 pathway that is likely to play a crucial role
in oral cancer invasion and metastasis.
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Protein tyrosine phosphorylation, under the control of 2
opposing chemical reactions catalyzed by protein tyrosine
kinase (PTK) and protein tyrosine phosphatase (PTP),
plays a vital role in various cellular functions [1]. Disturb-
ing the balance between PTK and PTP activities leads to
aberrant tyrosine phosphorylation, and has been linked to
the pathogenesis of many cancers [2]. Therefore, as a key
regulator of PTK activity, PTP has been considered a
potential drug targets for human cancers. Studies have
shown that some PTPs can function as oncogenes, includ-
ing src-homology 2 domain-containing tyrosine phos-
phatase 2 (SHP2), which is encoded by tyrosine-protein
phosphatase non-receptor type 11 [3-7]. In addition,
studies have also identified activate mutants of SHP2 in
patients with Noonan syndrome, juvenile myelomono-
cytic leukemia, acute myelogenous leukemia, and cer-
tain types of solid tumor [3,6-8]. SHP2 is a ubiquitously
expressed phosphatase that can transduce mitogenic,
pro-survival, cell-fate and pro-migratory signals from nu-
merous growth factors, cytokines, and extracellular-matrix
receptors [2,9-11].
Most deaths cause by cancer are attributed to meta-
static disease. Therefore, the prevention of metastasis
has become the focus of clinical attention [12]. In oral
cancer, metastasis to cervical lymph nodes or distant
organs is the primary prognostic indicator [13-15].
Through the invasion-metastasis cascade, cancer cells
can breach to the basement membrane to intravasate
and ultimately colonize distant sites, requiring reversible
changes in cell-cell and cell-extracellular-matrix (ECM)
adherence, destruction of matrix and stromal proteins,
and motility [16,17]. Several steps of this process can be
executed by cancer cells that activate the epithelial mesen-
chymal transition (EMT) [18], which is programmed by
pleiotropically acting transcriptional factors [19], and pre-
dominately controlled by various matrix metalloprotein-
ases (MMPs) [20].
Our understanding of invasion and metastasis remains
incomplete; thus, understanding the mechanisms under-
lying oral cancer invasion and metastasis is crucial for
facilitating the development of effective therapeutic strat-
egies against human oral cancer. Although SHP2 repre-
sents a promising target in cancer treatment, little is
known regarding the role of SHP2 involved in oral cancer
development. A recent study suggested that SHP2 influ-
ences breast-tumor initiating cells, and enhances breast
tumor maintenance and progression [9]. Therefore, we
hypothesized that SHP2 is involved in oral cancer inva-
sion and metastasis. We observed that SHP2 promotes
the invasion and metastasis in oral cancer, and identified
an ERK1/2-Snail/Twist1 pathway mediated by SHP2
that might play a major role in oral cancer invasion and
metastasis.Methods
Collection of tissue samples
Twenty-one pairs of primary oral cancer and histologically
normal oral mucosa adjacent to the tumors were obtained
after surgical resection at Chi-Mei Medical Center,
Liouying, Tainan, Taiwan, and stored at −80°C until use.
All of the human tissue specimens in this study were
processed and used with prior approval from the Chi-
Mei Medical Center Institutional Review Board and the
National Health Research Institute Institutional Review
Board (IRB1000202-R2). Samples containing > 70% tumor
cells were selected after microscopic examination of repre-
sentative tissue sections from each tumor.
Immunohistochemistry
Immunohistochemistry (IHC) was performed to evaluate
SHP2 expression in paraffin-embedded oral squamous cell
carcinoma specimens. The slides were stained with a SHP2
antibody (1:200, GeneTex Inc., Irvine, CA, USA) by using
an automatic slide stainer BenchMark XT (Ventana Med-
ical Systems), and counterstained with Harris hematoxylin.
Two independent pathologies evaluated the slides under a
light microscope. Immunoreactivity was classified by es-
timating the percentage (P) of tumor cells exhibiting
characteristic staining (from an undetectable level, 0%,
to homogeneous staining, 100%) and by estimating the
intensity (I) of staining (1, weak staining; 2, moderate
staining; and 3, strong staining). Results were scored by
multiplying the percentage of positive cells by the inten-
sity, (i.e. quick score Q = P × I; maximum = 300) [21].
Real-time reverse transcription-polymerase chain reaction
Real-time reverse transcription-polymerase chain reac-
tion (RT-PCR) analysis of SHP1, SHP2, Snail, Twist1
and GAPDH was conducted using SYBR-Green Master
Mix (Roche Applied Science, Basel, Switzerland) accord-
ing to the manufacturer's instructions. PCR amplifica-
tions were performed using an ABI7900 thermal cycler
by applying the following amplification conditions: 50°C
for 2 min, 95°C for 10 min, for 40 cycles at 95°C for 15 s
(denaturation step), and 60°C for 1 min (annealing/ex-
tension steps). GAPDH was amplified as an internal
control. All of the experiments were performed in dupli-
cate. Relative expression of the target genes (SHP1,
SHP2, Snail, and Twist1) to the control gene (GAPDH)
was calculated using the ΔCT method: relative expres-
sion = 2-ΔCT , where ΔCT = CT (Target) - CT (GAPDH) [22].
The oligonucleotide primers for human SHP1, SHP2,
Snail, Twist1, and GAPDH are listed as follows: SHP2,
forward: 5’-TCGTATAAATGCTGCTGAAAT-3’, reverse:
5’- TCCTGTTGTTGTAGTGTCT-3’; SHP1, forward: 5’-
GCAGTACAAGTTCATCTA-3’, reverse: 5’-CAGGTTC
TCATACACATC-3’; Snail, forward: 5’-ACGAGGTGTG
ACTAACTATG-3’, reverse: 5’-GACAAGTGACAGCCA
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ACAGTTGT-3’, reverse: 5’-GCACGACCTCTTGAGAA
T-3’; GAPDH, forward:5’-ACACCCACTCCTCCACCT
TT-3’, reverse: 5’- AGCCAAATTCGTTGTCATACC-3’.
Cell culture
HSC3 cells (JCRB, JCRB0623) were provided by Dr. Lu-Hai
Wang, Institute of Molecular and Genomic Medicine,
National Health Research Institute, Taiwan. The HSC3
cells were cultured in Dulbecco’s modified Eagle’s medium
supplemented with 100 μL/mL of fetal bovine serum [23].
Establishment of highly invasive oral cancer cell lines
The highly invasive HSC3 cell line was established using
the Falcon Cell Culture Inserts with a Matrigel coating
(BD Biosciences, CA, USA). Briefly, cells (5 × 104) were
harvested, re-suspended in a serum-free medium with
0.1-% bovine serum albumin (BSA) (Sigma-Aldrich, Inc.,
St. Louis, MO, USA), and then plated in a transwell
chamber. The chamber was incubated for 18 h with a
complete culture medium added to the lower chamber.
After 18 h of incubation, cells migrating to the lower
surface of the filter were collected [23]. This in vitro se-
lection protocol was used in selecting cells from 4 to 8
cycles to derive the highly invasive sub-lines, HSC3-Inv4
and HSC3-Inv8; in these terms, the number following
“Inv” denotes the number of cycles of selection. After in-
vasion selection, the lines were tested for their migratory
and invasive ability by performing a Boyden chamber
migration/invasion assay [24].
Cell proliferation assay
Cell viability was measured using the 3-(4, 5-dime
thylthiazol-2-yl)-2, 5-diphenyl-2H- tetrazolium bromide
(MTT) colorimetric assay. The HSC3 cells were plated
at 103 cells/well in a 96-well plate (100 μL/well) and
incubated for 24 h. After 24 h, the culture medium was
removed, and 200 μL of a fresh medium containing
20 μL of MTT (5 mg/mL; Sigma-Aldrich Japan, Tokyo,
Japan) was added to each well. The cells were incubated
at 37°C for 4 h. After 4 h, the liquid was discarded and
DMSO (200 μL/well) was added, after which the samples
were mounted on a micromixer for 15 min to make dis-
solve the blue granules in the samples thoroughly. The
culture plate was then placed on the microplate reader,
and optical density (OD) was measured at 570 nm [23].
SHP2 plasmid construction and transient transfection
Total RNA was isolated from normal human oral keratino-
cytes (HOK cells) by using the Trizol reagent (Life Tech-
nologies, New York, NY, USA). Two microgram aliquots
were reverse-transcribed using SuperScript II reverse tran-
scriptase (Life Technologies) and the oligo dT primer
according to the manufacturer’s instructions [22]. Thehuman SHP2 coding region (GeneBank: NM_002834) was
amplified by performing PCR using the forward primer 5’-
GGATCCATGACATCGCGGAGATGGTTT-3’, which in-
troduced a BamHI site, and the reverse primer 5’- GAA
TTCTTCATCTGAAACTTTTCTGCTG-3’, which intro-
duced an EcoRI site, under the following conditions: de-
naturing for 30 s at 94°C, annealing for 30 s at 62°C and
elongation for 1 min at 72°C for 35 cycles. The full-length
of SHP2 was subcloned into the constitutive mammalian
expression vector pCMV Tag 2B vector (Stratagene, La
Jolla, CA, USA). The SHP2C459S (SHP2C/S) mutant was
generated using the QuikChange Lighting Site-Directed
Mutagenesis kit (Agilent Technologies, Inc., Wilmington,
USA). The HSC3 cells were transfected with the pCMV
Tag 2B-SHP2 wild type (WT) or the SHP2C/S mutant and
empty vector by using a lipofectamine reagent (Life Tech-
nologies), according to the manufacturer’s protocol, and
then subjected to invasion, metastasis assays and western
blot analysis. The pEGFP-SHP2 WT and C/S mutant were
engineered by inserting a coding region into the SalI and
BamHI sites of pEGFP vector (Stratagene). The HSC3 cells
were transfected with the pEGFP-SHP2 WT or the SHP2
C/S mutant and empty vector, and harvested for use in the
immunoprecipitation assay.
Transfection of cells with siRNA
The HSC3 cells were transfected at 50% confluence with
SHP2 siRNA or a scrambled control (Invitrogen Stealth™
RNAi Negative Control LOGC, Life Technologies), Lipo-
fetamine RNAimax (Life Technologies) and Optimen I
(Life Technologies) according to the manufacturer's in-
structions [24]. The RNAi sequences for human SHP2
are listed as follows: SHP2#1, sense: 5’-UAA AUCGGU
ACUGUGCUUCUGUCUG-3’, antisense: 5’-CAGACAG
AAGCACAG ACCGAUUUA-3’; SHP2#2, sense: 5’-AA
UAUUUGUAUAUUCGUGCCCUUU C-3’, antisense: 5’-
GAA AGG GCACGAAUAUACAAAUAUU-3’. The tar-
get sequence for si-RNA is within the SHP2 coding
region.
Assay of SHP2 activity
SHP2 activity was analyzed using a Human Active SHP-2
kit (R&D Systems Inc., Minneapolis, MN, USA). Briefly,
cells were lysed in a lysis buffer ([50 mM HEPES,
0.1 mM EGTA, 0.1 mM EDTA, 120 mM NaCl, 0.5-%
Nonidet-P40 [NP-40], pH 7.5 supplemented with fresh
protease-inhibitor-mixture tablets (Roche Applied Sci-
ence). The SHP2 proteins were then immunoprecipi-
tated using active SHP2 immunoprecipitation beads
(R&D Systems Inc.), and washed 3 times in the lysis buf-
fer and 4 times in a phosphatase assay buffer (10 mM
HEPES, 0.1 mM EGTA, 0.1 mM EDTA, 0.5-% BSA,
1 mM dithiothreitol [DTT], pH 7.5). The phosphatase re-
action was initiated by incubating the immunocomplexes
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substrate I, DADEY (PO3) LIPQQG, according to the
manufacturer's instructions. Phosphatase activity was
determined using a microplate reader (SpectraMax 190
Absorbance Microplate Reader; Molecular Devices) at
620 nm.
Western blot analysis
The HSC3 cells were lysed in a RIPA buffer (50 mM Tris–
HCl, pH 7.8; 150 mM NaCl; 5 mM EDTA; 5 μL/mL of
Triton X-100; 5 μL/mL of NP-40; 1 μL/mL of sodium
deoxycholate) and subjected to western blot analysis with
the indicated antibodies. The bands were detected and re-
vealed by applying enhanced chemiluminescence (ECL)
using ECL western blotting detection reagents and
exposed to X-ray film (GE Healthcare, Little Chalfont,
Buckinghamshire, UK). Western blot images were captured
using an AlphaImager Mini System (Alpha Innotech,
Corp., San Leangro, CA, USA) [22]. Detailed antibodies
and reagents were described in the Additional file 1.
Immunoprecipitation
The HSC3 cells were transfected with the pEGFP-SHP2
or the C/S mutant and treated with a lysis buffer
(50 mM KP [pH 7.5], 100 mM KCl, 1 mM MgCl2, 10-%
glycerol, 0.2-% NP-40, 1 mM EGTA, 1 mM NaF, 1 mM
sodium pyrophosphate) supplemented with 1 mM DTT,
0.1 mM PMSF, 1 mM sodium orthovanadate and prote-
ase inhibitor cocktail tablets (Roche Applied Science).
Cell lysates were mixed with an antiserum against Flag,
GFP and the immunocomplexes were collected on pro-
tein A/G-Sepharose beads (Amersham Pharmacia Bio-
tec) [25]. Western blotting of proteins was performed as
described previously.
Cell migration and invasion assays
The migration and invasion of oral cancer cells were
assessed using Falcon Cell Culture Inserts with or without
a Matrigel coating (BD Biosciences, CA, USA). Briefly,
cells (5 × 104) were harvested, re-suspended in a serum-
free medium with 0.1-% BSA (Sigma-Aldrich, Inc., St.
Louis, MO, USA), and then plated in a transwell chamber.
The chamber was incubated for 18 h with a complete
culture medium added to the lower chamber. Cells mi-
grating to the lower chamber were stained with crystal
violet. Photomicrographs of 3–5 regions were captured
from duplicated chambers and the numbers of cells
were counted [26].
Immunofluorescence staining
The HSC3 cells grown on glass coverslips were fixed
with 4-% paraformaldehyde for 10 min, permeabilized
with 0.5-% Triton X-100 for 10 min, and blocked with
10-% BSA for 1 h. The cells were then incubated with arabbit anti-E-cadherin antibody (1:200) for 1 h, before
being incubated with FITC-conjugated anti-rabbit im-
munoglobulin (1:200; Life Technologies) for 30 min. Fluor-
escence images were captured using a Leica TCS SP5
confocal microscope [27].Assay of metastasis
Male CB17/SCID mice (aged 4–6 weeks; 20–25 g) were
obtained from BioLASCO Taiwan Co., Ltd and maintained
under specific pathogen-free conditions. All experiments
were approved by the Animal Care and Use Committee at
the National Health Research Institutes, Taiwan (NHRI-
IACUC-101117-A). HSC3 cells (1 × 105) were suspended
in 100 μM phosphate-buffered saline and injected into
the tail vein of mice (4 in each group), before being re-
ceived control si-RNA (Invitrogen Stealth™ RNAi Nega-
tive Control) or SHP2 siRNA (10 μL/g body weight)
mixed with the Invivofectamine transfection reagent
(Life Technologies) through tail vein injection (100 μL)
every 7 d for the next 5 wks. The mice were sacrificed
5 weeks after the injection of HSC3 cells [28-30]. The
entire lung was removed, fixed, embedded in paraffin
and then sectioned for hematoxylin and eosin (H&E)
staining. Tissue images were captured using a Zeiss
Mirax Scan 150 microscope (Carl-Zeiss, Oberkochen,
Germany). SHP2 siRNA, sense: 5’-UAA AUCGGUACU
GUGCUUCUGUCUG-3’, antisense: 5’-CAGACAGAAG
CACAG ACCGAUUUA-3’.Cellular fractionations
The cytoplasmic and nuclear protein fractions of HSC3
cells were extracted using a NE-PER* Nuclear and
Cytoplasmic Extraction Kit (Thermo Fisher Scientific,
Yokohama, Japan) according to the manufacturer's in-
structions [31]. Briefly, cells were harvested in cytosol
fractionation buffer supplemented with fresh phos-
STOP Phosphatase and Protease Inhibitor Cocktail
Tablets (Roche Applied Science) and incubated on ice
for 10 min before being centrifuged at 16 000 × g for
10 min. The precipitated pellet was solubilized with a
nuclear fractionation buffer and then centrifuged at
16000 × g for 10 min.MMP-2 secretion assay
A MMP-2 ELISA Kit (EMD Millipore, Inc., Darmstadt,
Germany) was used to detect MMP-2 secretion. Briefly,
conditioned medium were collected and subjected to an
immobilized capture antibody specific for MMP-2. After
unbound material was washed away, a synthetic substrate
was added to measure absorbance using a spectropho-
tometric plate reader according to the manufacturer's
instructions.
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All data were analyzed using the Student’s t test and are
presented as the mean ± SD. Difference were considered
to be statistically significant at *P < 0.05.
Results
Upregulation of SHP2 expression correlates with the
migratory and invasive ability of oral cancer cells
To assess the potential role of SHP2 in oral tumorigen-
esis, we evaluated SHP2 expression in human oral tu-
mors, and paired and histologically normal oral mucosa
adjacent to the tumors. We subjected 2 type tissue sam-
ples to IHC staining for SHP2 and observed a signifi-
cantly higher SHP2 in tumor cells than in histologically
normal oral mucosa adjacent to the tumors (Figure 1A).
Real-time quantitative RT-PCR analysis supported these
results and indicated significantly higher levels of the
SHP2 transcript in tumor tissue than in histologically
normal oral mucosa adjacent to the tumors (Figure 1B).
To investigate the biological functions of SHP2 in oral
tumorigenesis, we isolated highly invasive clones from
oral cancer cells by using an in vitro invasion assay. We
used 4–8 cycles of HSC3 cells, which have modest mi-
gratory and invasive ability among oral cancer cell lines
(data not shown), to derive the highly invasive clones,
HSC3-Inv4 and HSC3-Inv8. The growth of these clones
was the same as that of the parental cells (Figure 1C),
but the number of HSC3-Inv4 cells that migrated through
the filter was significantly higher than the number of par-
ental cells that migrated through the filter (Figure 1D).
We observed significantly upregulated SHP2 expressions
in the HSC3-Inv4 and HSC3-Inv8 clones in comparison
with the parental cells (Figure 1E). We observed no sig-
nificant difference in the levels of the SHP1 transcript in
the clones and parental cells (Additional file 2: Figure S1).
SHP1 is a high homolog of SHP2. Therefore, these results
suggested that SHP2 may exclusively be responsible for
the migration and invasion of oral cancer cells.
SHP2 activity is required for the migration and invasion
of oral cancer cells
To determine whether SHP2 is involved in regulating oral
cancer migration and invasion, we knocked down SHP2 by
using specific si-RNA. As expected, when we downregu-
lated SHP2 expression, the oral cancer cells exhibited mark-
edly reduced migratory and invasive ability (Figure 2A). We
observed similar effects on the invasive ability of the HSC3-
Inv4 and HSC3-Inv8 cells (Figure 2B). Collectively, our re-
sults indicated that SHP2 plays a crucial role in migration
and invasion in oral cancer cells.
Considering the crucial role of SHP2 activity in various
cellular functions, we then investigated whether SHP2
activity is required for migration and invasion of oral
cancer cells. We generated a flag-tagged SHP2 WT orphosphatase-dead SHP2 C459S mutant in HSC3 cells.
When we analyzed the cell migration or invasion, we
observed that the SHP2 mutant abrogated cell migra-
tion and invasion elicited by the SHP2 WT (Figure 2C).
Overall, these data indicated that the catalytic activity of
SHP2 is required for the migration and invasion of oral
cancer cells.
Critical events associated with enhanced invasiveness in
oral cancer cells
As shown in Figure 3A, we evaluated the changes in
EMT-associated E-cadherin and vimentin in highly inva-
sive oral cancer cells. Our results indicated that the ma-
jority of the parental HSC3 cells were polygonal in shape
(Figure 3A, left upper panel); whereas, the HSC3-Inv4
cells were rather spindle shaped (Figure 3A, right upper
panel), with downregulated of E-cadherin protein and
upregulated of vimentin protein (Figure 3B). When we
evaluated the levels of the transcripts of EMT regulators
Snail/Twist1, we observed significant upregulation of
Snail/Twist1 mRNA expression levels in the highly inva-
sive clones generated from the HSC3 cells (Figure 3C).
We then tested the medium from the highly invasive
clones to evaluate the secretion of MMP-2. As shown in
Figure 3D, increased MMP-2 secretion from oral cancer
cells significantly correlated with increased cell invasion.
While we analyzed the medium from SHP2-depleted cells,
we observed significantly reduced MMP-2 (Figure 3E).
Collectively, these results suggested that SHP2 exerts its
function in several critical stages that contribute to the ac-
quirement of invasiveness during oral cancer metastasis.
SHP2 regulates Snail/Twist1 expression through ERK1/2
signaling
To identify the potential biochemical pathways that rely
on SHP2 activity, we analyzed total tyrosine phosphoryl-
ation in SHP2 WT- and C459S mutant-expressing cells.
As shown in Additional file 3: Figure S2, we observed in-
creased protein phosphorylation in mutant-expressing
cells, particularly those migrating around 40–50 kD on
the gel, compared with SHP2 WT-expressing cells. We
thus hypothesized that p44/42 (ERK1/2) signaling might
trigger nuclear events because the phosphorylation of
ERK1/2 leads to its translocation to the nucleus, which is
required for the induction of several cellular responses. By
immunoprecipitating exogenously expressed EGFP-tagged
SHP2 and immunoblotting using anti-ERK1/2 as a probe,
we identified an association between ERK1/2 and SHP2 in
cells expressing SHP2 WT and mutant (Figure 4A). We
observed markedly increased ERK1/2 phosphorylation in
phosphatase-dead cells (Figure 4A), indicating that SHP2
catalytic activity plays a major role in the regulation of
ERK1/2 activity, but is not required for the assembly of
the ERK1/2/SHP2 complex.
Figure 1 Upregulation of SHP2 expression correlates with the migratory and invasive ability of oral cancer cells. (A) Oral tumors and
histologically normal oral mucosa adjacent to the tumors were stained with anti-SHP2 antibody. The IHC semi-quantitative score was derived by
two independent pathologies, multiplying the staining intensity by the percent of tumor cells stained. IHC scores for each core of a specimen
were averaged (n = 19) and statistically analyzed. (B) cDNA from paired oral tumor samples were subjected to RT-PCR (n = 18). Relative
expression of SHP2 transcript to internal control gene, GAPDH was calculated as described in Materials and Methods. (C) Cell proliferation was
performed by MTT assay. Cells were counted at 570 nm wavelength and the relative absorbance was represented as mean ± SD from at least
four independent experiments. (D) Cells were seeded onto the transwell chamber coated with matrigel as described in Methods. Images are
representative of cells adhering to the lower chamber after the invasive process. Cells were stained with crystal violet solution, and images were
taken by photography (Upper panel). Invading cells per file on the lower chamber were counted. The data are expressed as mean ± SD from
three independent experiments; P < 0.05. (Lower panel) (E) An increased SHP2 transcript level was associated with higher invasive ability of HSC3
cells. The expression of SHP2 for HSC3-Inv4 and HSC3-Inv8 was normalized to HSC3 parental cells.
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Figure 2 SHP2 depletion or catalytic deficiency mutant inhibits migration and invasion of oral cancer cells. (A) Cells transfected with
SHP2 si-RNA (si-SHP2#1 or si-SHP2#2) or Negative control (si-NC) were seeded onto the transwell chamber coated with or without matrigel as
described in Materials and Methods. Cells adhering to the lower chamber after the migration or invasive process were stained with crystal violet
solution, and images were taken under bright-field microscopy at 40×. An obvious decrease in migration (Upper panel) and invasion (middle
panel) ability was noted in HSC3 cells transfected with SHP2 si-RNA (si-SHP2#1 or si-SHP2#2) compared to Negative control (si-NC). Western blot
shows the expression of SHP2 in HSC3 cells transfected with SHP2 si-RNA or Negative control (Lower panel). (B) Effect of SHP2 knockdown on
invasion of HSC3-Inv4 and HSC3-Inv8 cells (Upper panel, left and right, respevtively). The quantitative data are expressed as mean ± SD from
three independent experiments; *, P < 0.05 (Middle panel). Western blot shows the expression level of SHP2 in HSC3-Inv4 and HSC3-Inv8 cells
transfected with SHP2 si-RNA or Negative control (Lower panel, left and right, respectively). (C) A dramatic decrease in migration (Left panel) and
invasion ability (Middle panel) was observed in HSC3 cells transfected with SHP2 C459S mutant (SHP2C/S) compared to the SHP2 wild type
(SHP2WT). Evaluation on SHP2 activity of the cells transfected with indicated constructs. Experiments were done in triplicate at least, and values
are indicated as mean ± SD. *, P < 0.05 (Right upper panel). Western blot shows the expression level of transfected flag-SHP2 proteins (Right
lower panel).
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phosphorylation leads to its accumulation in the nu-
cleus (Figure 4B), we then investigated whether Snail
and Twist1 are possible downstream effectors of ERK1/
2 signaling. In the presence of a selective ERK1/2inhibitor, FR180204, we observed a dose-dependent re-
duction at the transcript levels of Snail/Twist1 in oral
cancer cells (Figure 4C). However, in the absence of
SHP2 expression, we observed increased transcript levels
of Snail/Twist1 (Figure 4D), as well as increased ERK1/2
Figure 3 Characteristics of highly invasive clone, HSC3-Inv4 derived from parental HSC3 cells. (A) Bright file microscopy images of HSC3
parental and HSC3 Inv 4 (20×, Upper panels). Cells were stained with E-cadherin and images were taken under fluorescence at 60× (Lower panels).
(B) Expressions of E-cadherin and vimentin were analyzed by Western blot with indicated antibodies; GAPDH as a loading control. (C) Increased Snail
(Upper panel) and Twist1 (Middle panel) transcript levels were observed in HSC3-Inv4 and HSC3-Inv8 compared to HSC3 parental cells. Experiments
were done at least in triplicate and values indicated as mean ± SD. *, P < 0.05 compared with the adjacent normal in each case. Western blot shows
the expression level of Snail and Twist1 in HSC3-parental, HSC3-Inv4 and HSC3-Inv8 cells (Lower panel). (D) Status of MMP-2 secretion on highly
invasive clones. Medium collected from HSC3 parental, HSC-Inv4 and HSC3-Inv8 cells were subjected to MMP-2 secretion analysis. Significantly
increased amounts of MMP-2 were seen in selected sub-cell lines compared to parental cells. (E) SHP2 depletion resulted in decreased MMP-2
secretion in HSC3 parental, HSC3-Inv4 and HSC3-Inv8 cells.
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Figure 4 SHP2 acts on Snail/Twist1 through negatively regulating ERK1/2 activity. (A) SHP2 forms a complex with ERK1/2. Total cell lysates
were prepared, and SHP2 was immunoprecipitated from HSC3 cells expressing EGFP-tagged SHP2 wild type or catalytic-defective SHP2 (SHP2C/S).
SHP2 in association with active ERK1/2 in these cells was detected by SDS-PAGE and immunoblotting with anti-phospho-ERK1/2, ERK1/2, SHP2
and GFP. (B) Nuclear localization of phospho-ERK1/2 is enriched in HSC3-Inv4 and HSC3-Inv 8 compared to HSC3 parental cells. (C) Treatment
of ERK inhibitor with indicated concentration for 6 hours significantly reduced Snail or Twist1 mRNA expression in HSC3 parental and HSC3-Inv8
cells. (D) SHP2 depletion significantly increased Snail orTwist1 mRNA expression in HSC3 parental and HSC3-Inv8 cells (Upper panel and lower
panel, respectively.). Experiments were done in triplicate and values indicated as mean ± SD. *, P < 0.05 compared with adjacent normal in each
case. (E) Knockdown of SHP2 increases both cytosol and nuclear localization of phospho-ERK1/2 in oral cancer cells. Poly ADP-ribose polymer-
ase (PARP) was used as a nuclear marker.
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SHP2 modulates Snail/Twist1 at a transcript level by
negatively regulating ERK1/2 activity.
SHP2-depleted oral cancer cells exhibit reduced ability for
lung metastasis
We evaluated the effects of SHP2 attention on the me-
tastasis of oral cancer cells toward the lung to establish
the potential for developing SHP2 as a target for human
oral cancer treatment. As shown in Figure 5, we ana-
lyzed the lungs of mice with HSC3 xenografts and SHP2
si-RNA administered through tail vein injection by using
H&E staining. Analysis of lung tissue sections indicatedFigure 5 SHP2 promotes lung metastasis. SHP2 si-RNA delivered via tail
cells. Representative images showing H&E staining of lung tissues were tak
panel). Black lines delineate tumor tissue (T). Quantitative metastasis index
control group, HSC3 cells (Lower panel).that HSC3 tumors with SHP2 knockdown exhibited an
approximate 70% reduction in metastatic capacity, com-
pared with those with control si-RNA (Figure 5, lower
panel). Overall, the result supported that SHP2 inhibits
the migration, invasion, and metastasis of oral cancer
cells, and indicated that SHP2 is a potential target for
oral cancer treatment.
Discussion
Studies have reported that SHP2 is overexpressed and/or
hyperactive in multiple malignancies [3,4,6,7,24,32]; how-
ever, the role of SHP2 in oral cancer has yet to be eluci-
dated fully. Our results indicated that the levels of SHP2vein injection dramatically reduced the metastatic capacity of HSC3
en under bright-field at 200× using a scanning microscope (Upper
was indicated as mean ± SD. *, P < 0.05 compared with the
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significantly upregulated in tissue samples obtained
from patients with oral cancer, and that SHP2 is re-
quired for the in vitro invasion of oral cancer cells to
Matrigel (Figure 2A and B) and in vivo metastasis of
oral cancer cells toward the lung in mice (Figure 5).
Considering the requirement of SHP2 activity for the
migration and invasion of oral cancer cells (Figure 2C),
and the significant upregulation of SHP2 activity in oral
cancer cells (Additional file 4: Figure S3), we investi-
gated whether SHP2 mutations cause the observed in-
crease in SHP2 activity in oral cancer cells. We did not
identify any SHP2 mutations in oral cancer cell lines
and tissue samples (data not shown), supporting the find-
ings of previous studies that SHP2 mutations rarely occur
in solid tumors [3,9,32]. Therefore, SHP2 hyperactivity in
oral cancer cells might result from the inappropriate
expression of SHP2 binding protein, which causes the ab-
errant activation of SHP2 [33,34]. However, additional
studies are required to confirm this hypothesis.
In the study, we isolated highly invasive oral cancer cell
clones to establish useful method for investigating the
mechanisms underlying the invasion and metastasis of
oral cancer cells. We evaluated critical stages in invasion-
metastasis cascade, including EMT and MMPs (Figure 3).
Previous studies have reported reduced E-cadherin ex-
pression in oral cancer cells with highly invasive ability,
and we observed similar results in this study. The methy-
lation of E-cadherin might cause the downregulation of E-
cadherin expression, which plays a major role in invasion
and metastasis in oral cancer. Recent studies have also
shown that Snail-dependent EMT in oral cancer cells oc-
curs as a result of the downregulation of E-cadherin [35],
and that Twist1, another important transcriptional factor
involved in the EMT, was upregulated in cells isolated
from patients with metastatic oral squamous cell carcin-
oma [36]. The highly invasive clones also exhibited
changes in the hallmarks of the EMT and transcriptional
factors responsible for the EMT, providing a suitable
cell model for the analysis of the detailed mechanisms
involved in oral cancer metastasis. Our results indicated
that SHP2 increases MMP-2 secretion in oral cancer
cells (Figure 3E). Previous studies have suggested that
the ERK1/2 pathway increases the invasion of several
cancers by increasing MMP-2/9 expression and activity
[37-40]. However, treatment of the oral cancer cells with
ERK inhibitor resulted in no significant changes in
MMP-2 secretion (data not shown), indicating that sig-
naling pathways other than ERK1/2 might be involved
in SHP2-mediated MMP-2 secretion.
Our results suggest a mechanism which SHP2 down-
regulates ERK1/2 activity and, thus, regulates Snail/
Twist1 expression (Figure 4). The downregulation of epi-
dermal growth factor receptor activity by SHP2 mightdownregulate ERK1/2 signaling (Additional file 5: Figure S4).
However, the interaction between SHP2 and ERK1/2 in
oral cancer cells suggests that the effects of SHP2 on
ERK1/2 activity occur through direct or indirect inter-
action between the enzymes (Figure 4A). Therefore,
the interaction partners of SHP2 in oral cancer cells must
be investigated to elucidate the detailed mechanisms
underlying the effects of SHP2 on ERK1/2 regulation. The
functional consequences of SHP2-ERK1/2-Snail/Twist1
signaling have yet to be established. SHP2-mediated Snail/
Twist1 regulation through ERK1/2 may not be critical to
the EMT. Alternatively, Snail/Twist1 may be involved in
steps other than the EMT during oral cancer progress.
Additional studies are required to evaluate these
hypotheses.
Because no selective SHP2 inhibitor was available, we
used a specific SHP2 si-RNA to evaluate the role of
SHP2 in the metastasis of oral cancer cells toward the
lung in mice (Figure 5). PTPs have increasingly attracted
attention as targets for novel cancer therapies. Our in vivo
si-RNA knockdown data indicated that SHP2 siRNA can
be applied in patients with oral cancer. Studies have indi-
cated that SHP2 is responsible for the basal suppression of
pSTAT1 and subsequent antigen processing machinery
component-mediated immune escape in head and neck
cancer cells [24], suggesting that SHP2 can be targeted to
enhance T-cell-based cancer immunotherapy. Overall,
these findings emphasize the potential use of SHP2 as a
treatment target for oral cancer.
Conclusions
In this study, we report that SHP2 is a potential target
for oral cancer treatment. We overexpressed SHP2 in oral
cancer cells, and attenuated SHP2 to observe reduced in-
vasion and metastasis. Our result indicated that the down-
regulatory effects of SHP2 on ERK1/2 might regulate
Snail/Twist1 mRNA expression and play a crucial role in
oral cancer invasion and metastasis. These findings pro-
vide a rationale for future investigation into the effects of
small-molecule SHP2 inhibitors on oral cancer progres-
sion, and can facilitate the development of novel treat-
ments for human oral cancer.
Additional files
Additional file 1: Suplemetary materials and Methods.
Additional file 2: Figure S1. SHP1 transcriptional level is not associated
with highly invasive ability in oral cancer cells. No significant difference in
SHP1 transcript was observed between parent and highly invasive clones
derived from HSC3 cells. The expression of SHP1 for HSC3-Inv4 and
HSC3-Inv8 was normalized to HSC3 parental cells. Data are representative
of three independent experiments.
Additional file 3: Figure S2. SHP2 catalytic-defective expressing cells
showed enhanced tyrosine phosphorylation of protein. The cells
expressing SHP2 wild type or C/S mutant were lysed, and subjected to
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http://www.biomedcentral.com/1471-2407/14/442immunoblotting with anti-phospho-tyrosine. Data are representative of
three independent experiments.
Additional file 4: Figure S3. Profile of SHP2 activity in oral cancer cell
lines (OC3, OECM1, HSC3, and SCC4). Experiments were done in triplicate
at least, and values are indicated as mean ± SD. HOK, normal cells.
Additional file 5: Figure S4. SHP2 negatively regulates EGFR activity in
oral cancer cells. Total cell lysates were prepared, and SHP2 was
immunoprecipitated from HSC3 cells expressing EGFP-tagged SHP2 wild
type or catalytic-defective SHP2 (SHP2C/S). SHP2 in association with active
EGFR in these cells was detected by SDS-PAGE and immunoblotting with
anti-phospho-EGFR, EGFR, and SHP2. GAPDH as loading control. Data are
representative of three independent experiments.
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